Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

NCT00822211 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00822211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00822211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2008
Completion date
December 31, 2009
Enrollment
404 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus